A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma

Trial Profile

A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Pazopanib (Primary) ; Trametinib (Primary) ; Paclitaxel
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PACMEL
  • Most Recent Events

    • 05 Apr 2017 Results of phase II part of this study (n=111) presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 11 Apr 2016 Status changed from recruiting to completed.
    • 23 Feb 2016 Planned End Date changed from 31 Jan 2016 to 31 Mar 2016 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top